European Commission Withdraws EU Marketing Authorisation For Zinplava At Merck Sharp & Dohme B.V.’s Request After Permanent Discontinuation For Commercial Reasons
On 20 October 2026, the European Commission withdrew the marketing authorisation for Zinplava (bezlotoxumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck
Merck stopped selling a medicine called Zinplava in Europe. When a company pulls a product for business reasons, watch if other products are doing better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.